We are offering our innovative "human robust, reproducible & reliable respiratory platform" that is reconstructed from normal and diseased human lung tissue, to dramatically enhance and accelerate respiratory drug discovery.
SCROLL
Advancing Respiratory Drug Discovery: Yuki Yamamoto to Present Lung Organoid Breakthroughs at MPS World Summit 2025
Our advertisement feature, Lung organoids could speed development of treatments, was published on 15 May 2025, as part of Technology Feature Organoids in the online version of Nature, a weekly international journal publishing the finest peer-reviewed research in science and technology.
Presentation at a pandemic preparedness symposium in San Diego, hosted by J&J & BARDA
Yuki Yamamoto, CEO of HiLung, present our activities at Imperial Lung and Airway Organoid Workshop, Imperial College London 29 April 2024.
We have a booth at the Annual Meeting of the Japanese Society of Virology again this year.
We have experience in dramatically accelerating the drug discovery process for respiratory diseases based on our extensive experience and recent findings on "lung stem cell biology", including those based on human iPS cell differentiation technology. Our services will assist in efficient preclinical discovery of highly effective therapeutic drug candidates based on well-founded human pathophysiology models we have developed. We will continue to adapt and optimize our human lung model servicing and packaging to better fit our clients' needs, while establishing the additional science and the track record ultimately needed to bring about cell and tissue therapies for respiratory organs.
VIEW MOREOur core technologies and engineering have for the first time enabled a very reliable mass production of human respiratory epithelial cells that essentially replicates human biology. We are applying this core technology to replicate disease pathophysiology for drug discovery purposes and normal physiology for toxicity studies, and will further strengthen it to enable cell therapy and tissue transplantation purposes.
VIEW MOREWe are not currently recruiting.